Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. pipelinereview.com › jjp-biologics-announces-positive-decision-to-execute-aJJP Biologics Announces Positive Decision to Execute a...

    Hace 14 horas · Alongside Linear IgA Bullous Dermatosis (LABD), JJP-1212 is being developed for a wide range of autoimmune- and fibrotic diseases where IgA is known to have significant pathogenic involvement (e.g. rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, neutrophilic asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, hidradenitis ...

  2. ceo.ca › @businesswire › jjp-biologics-announces-positive-decision-to-executeJJP Biologics Announces Positive Decision to Execute a...

    Hace 14 horas · JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants (EudraCT: 2023-508661-33-00) with their potential first-in-class anti-CD89 antagonist, JJP-1212.

  3. www.ansa.it › sito › notizieJJP Biologics Announces Positive Decision to Execute a...

    Hace 14 horas · JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody ...

  4. Videos

    Ver todo

  5. www.businesswireindia.com › jjp-biologics-announces-positive-decision-to-executeJJP Biologics Announces Positive Decision to Execute a...

    Hace 7 horas · JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial ...

  6. khabreelal.com › pressrelease › englishJJP Biologics Announces Positive Decision to Execute a...

    Hace 7 horas · Business Wire India. JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants (EudraCT: 2023-508661-33-00) with their potential first-in-class anti-CD89 antagonist, JJP-1212.

  7. www.vbdata.cn › intelDetail › 173713创新抗体疗法开发商JJP Biologics宣布积极决定执行抗炎 ...

    Hace 14 horas · WARSAW, Poland--(BUSINESS WIRE)--JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants (EudraCT: 2023-508661-33-00) with their potential first-in-class anti-CD89 antagonist, JJP-1212..

  8. www.einnews.com › pr_news › 715458120JJP Biologics Announces Positive Decision to Execute a...

    Hace 7 horas · JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European